Log In
BCIQ
Print this Print this
 

minocycline (Minocin IV) (RPX-602)

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionInjectable formulation of minocycline
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBacterial infection
Indication DetailsTreat multidrug-resistant infections due to Acinetobacter species
Regulatory Designation U.S. - Qualified Infectious Disease Program (Treat multidrug-resistant infections due to Acinetobacter species)
PartnerThe Medicines Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$474.0M

$140.0M

$334.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/09/2013

$474.0M

$140.0M

$334.0M

Get a free BioCentury trial today